Navigation Links
AEterna Zentaris Receives US$10 Million from Institutional Investors
Date:6/24/2009

fer to buy any of AEterna Zentaris' common shares or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any su
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Bill Jacobs Automotive, a group of car dealerships headquartered ... the Heartland Blood Center and offering free oil change coupons ... place Saturday, Jan. 18 at the Bill Jacobs Cadillac and ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Programs to Include Response Prediction to Ovarian Cancer ... Differentiation of Small Cell From Non-Small Cell Lung Cancer, In Addition, ... Cancer Patients, Which may Serve as the Basis for a Future ... Test ...
... Lead Discovery, COPENHAGEN, June 18 Nuevolution ... drug discovery collaboration with Merck & Co.,Inc., ... to identify novel small molecule leads against several ... uses innovative DNA,labeling to allow fragment-based drug screening ...
... HARTFORD, Conn., June 17 The Connecticut,Technology Council (CTC) ... in,partnership with accounting firm UHY LLP this November, to ... will be,recognized on the basis of revenue growth over ... and minimum revenues of $3 million in,the fourth year., ...
Cached Biology Technology:Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 4Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 5Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2Connecticut Technology Council to Recognize Fast Growing Technology Companies 2
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
(Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
(Date:4/22/2014)... Mass. Scientists at the University of Massachusetts Amherst ... Brazil, this week report that they have discovered a ... tributaries of the Negro River in the Amazonia State ... Amherst, with Adlia Nogueira and Jos Antnio Alves-Gomes of ... issue of the journal Proceedings of the Natural ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2
... drug has lowered blood sugar levels and inflammation in mice ... be added to the arsenal of drugs used by millions ... The drug consists of a synthetic molecule that stops the ... or MIF. This protein is implicated in a number of ...
... the Australian National University, Research School of Chemistry, has ... Otting is on the editorial board of Springer,s ... Award is granted in recognition of a researcher,s entire ... had a significant impact on their own discipline. The ...
... and the University of Ottawa have identified a promising new ... the leading inherited cause of death in infants and toddlers. ... found that an enzyme called RhoA is overly active in ... can greatly increase survival. The study is published in ...
Cached Biology News:Study points to potential new drug for type 2 diabetes 2Study points to potential new drug for type 2 diabetes 3Study points to potential new drug for type 2 diabetes 4Study opens new avenue for developing treatments for genetic muscle-wasting disease 2
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: